Mineralys Therapeutics, Inc.
NASDAQ: MLYS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jon Congleton
- Employees
- 51
- Headquarters
- Radnor, United States
- IPO year
- 2023
- Market cap
- $1.7B
- Website
- https://mineralystx.com
Loading MLYS…
Loading profile data…Frequently asked questions about MLYS
What does Mineralys Therapeutics, Inc. (MLYS) do?
Mineralys Therapeutics, Inc. (MLYS) is a pioneering biopharmaceutical company currently advancing through clinical trials. Its primary focus lies in creating innovative treatments for high blood pressure and its related cardiovascular complications. The company's leading investigational drug is lorundrostat. This exclusive, orally administered c...
Where does MLYS trade?
Mineralys Therapeutics, Inc. (MLYS) trades on the NASDAQ Global Select.
What sector is MLYS in?
Mineralys Therapeutics, Inc. (MLYS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Mineralys Therapeutics, Inc.?
Jon Congleton is the chief executive officer of Mineralys Therapeutics, Inc. (MLYS).
Where is Mineralys Therapeutics, Inc. headquartered?
Mineralys Therapeutics, Inc. is headquartered in United States.
Does MLYS pay a dividend?
Mineralys Therapeutics, Inc. (MLYS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MLYS go public?
Mineralys Therapeutics, Inc. (MLYS) completed its initial public offering in 2023.